Feb 19 (Reuters) - Hims & Hers Health said on Thursday it will acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion, as the U.S. telehealth firm pushes into international markets to expand its personalized-care business, sending its shares up nearly 7% premarket.

The deal would give Hims & Hers a foothold in Australia and Japan while deepening its presence in the United Kingdom, Germany, and Canada through partnerships with established regional operators.

Hims & Hers will pay about $240 million in cash at closing, with the remainder structured as deferred payments over 18 months and performance-based earnouts through early 2029. The deal is expected to close in mid-2026, subject to regulatory approvals.

Eucalyptus operates several consumer-focused brands globally, including weight-loss program Juniper and men's telehealth brand Pilot, and has served more than 775,000 customers, according to Hims & Hers.

"We've always taken a local-led approach to global expansion, where we partner with experts to enter new markets in a way that makes room for the nuance of each territory," Hims & Hers Chief Executive Andrew Dudum said.

Tim Doyle, currently CEO of Eucalyptus, will oversee the international business at Hims & Hers after the deal is closed.

The deal comes as the company navigates significant regulatory and legal headwinds in its core U.S. market. Drugmaker Novo Nordisk sued it following an FDA crackdown that forced Hims & Hers to pull a $49 compounded version of Novo's blockbuster weight-loss drug Wegovy.

Hims & Hers has been accelerating its international expansion in response to domestic pressures. Last year, Hims acquired London-based startup Zava for an undisclosed amount, allowing it to launch its offerings in Germany, France and Ireland and reach more international patients.

Hims & Hers said it expects the deal to deliver category leadership in Australia and help it become a leading telehealth provider in the UK and Germany within the next two years.